Clinical data for NSCLC remain scarce, but pyrotinib has higher antitumor activity than afatinib in HER2-mutant organoid systems82, and a phase II trial enrolling chemotherapy-pretreated patients with HER2-mutant advanced lung adenocarcinoma has indicated promising activity, with a PFS of 6.9 months83. The gene discussed is ERBB2; the disease is lung adenocarcinoma.